公开(公告)号：US12171830B2

公开(公告)日：2024-12-24

申请号：US17686536

申请日：2022-03-04

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Daisuke Kameoka ,  Toru Yoshizawa ,  Megumi Numata ,  Hitoshi Sasaki ,  So Yamaguchi ,  Hiroko Murata ,  Naoka Hironiwa

IPC: C07K16/28 ,  A61K9/08 ,  A61K9/19 ,  A61K39/395 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/28 ,  A61K39/00 ,  C07K14/715

Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.

公开(公告)号：US11952422B2

公开(公告)日：2024-04-09

申请号：US16769299

申请日：2018-12-04

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Shun Shimizu ,  Shu Wen Samantha Ho ,  Naoka Hironiwa ,  Mika Sakurai ,  Taro Miyazaki ,  Tomoyuki Igawa

IPC: C07K16/28 ,  C07K16/30 ,  C40B30/04

CPC classification number: C07K16/2809 ,  C07K16/2863 ,  C07K16/2878 ,  C07K16/303 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2317/92 ,  C40B30/04

Abstract: Antigen-binding domains that are capable of binding to CD3 and CD137 but do not bind to CD3 and CD137 at the same time and methods of using the same are provided. Methods to obtain antigen binding domains which bind to two or more different antigen more efficiently are also provided.

公开(公告)号：US11891434B2

公开(公告)日：2024-02-06

申请号：US15988348

申请日：2018-05-24

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki Igawa ,  Shinya Ishii ,  Miho Funaki ,  Naoka Hironiwa ,  Atsuhiko Maeda ,  Junichi Nezu ,  Yoshinao Ruike ,  Takeshi Baba ,  Shun Shimizu

IPC: C07K16/18 ,  C07K16/24 ,  C07K16/28 ,  C07K16/42 ,  G01N33/53

CPC classification number: C07K16/18 ,  C07K16/248 ,  C07K16/2866 ,  C07K16/4291 ,  G01N33/53 ,  C07K2317/565

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

公开(公告)号：US11739149B2

公开(公告)日：2023-08-29

申请号：US16704464

申请日：2019-12-05

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Tomoyuki Igawa ,  Shojiro Kadono ,  Naoka Hironiwa ,  Mika Sakurai

IPC: C07K16/28 ,  C07K16/42 ,  C07K16/30

CPC classification number: C07K16/2809 ,  C07K16/2848 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2875 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/4283 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/70

Abstract: The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.

公开(公告)号：US20220184210A1

公开(公告)日：2022-06-16

申请号：US17686536

申请日：2022-03-04

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Daisuke Kameoka ,  Toru Yoshizawa ,  Megumi Numata ,  Hitoshi Sasaki ,  So Yamaguchi ,  Hiroko Murata ,  Naoka Hironiwa

IPC: A61K39/395 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26 ,  A61K47/10 ,  C07K16/28 ,  A61K9/08

Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.

公开(公告)号：US20210230311A1

公开(公告)日：2021-07-29

申请号：US17225273

申请日：2021-04-08

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi NEZU ,  Atsushi Narita ,  Takahiro Ishiguro ,  Mika Sakurai ,  Hirotake Shiraiwa ,  Naoka Hironiwa ,  Tomoyuki Igawa ,  Yumiko Kawai

IPC: C07K16/46 ,  C12N15/09 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30 ,  C12N5/10

Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

公开(公告)号：US09975966B2

公开(公告)日：2018-05-22

申请号：US15467654

申请日：2017-03-23

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Junichi Nezu ,  Atsushi Narita ,  Takahiro Ishiguro ,  Mika Sakurai ,  Hirotake Shiraiwa ,  Naoka Hironiwa ,  Tomoyuki Igawa ,  Yumiko Kawai

IPC: C07K16/46 ,  C07K16/30 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/30 ,  C07K16/303 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94 ,  C12N5/10 ,  C12N15/09

Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

公开(公告)号：US12030955B2

公开(公告)日：2024-07-09

申请号：US16767085

申请日：2018-11-28

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Tomoyuki Igawa ,  Hiroyuki Ishikawa ,  Naoka Hironiwa ,  Tatsuya Kawa

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: C07K16/303 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/569

Abstract: The present invention relates to polypeptides containing an antigen-binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen-binding activity of the antigen-binding domain, and having a longer half-life than that of the antigen-binding domain existing alone; methods for producing and screening for the polypeptides; pharmaceutical compositions containing the polypeptide; methods for producing and screening for a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH; and fusion polypeptide libraries including a single-domain antibody whose antigen-binding activity is inhibited by its association with particular VL, VH or VHH.

公开(公告)号：US11260125B2

公开(公告)日：2022-03-01

申请号：US17346421

申请日：2021-06-14

Applicant: Chugai Seiyaku Kabushiki Kaisha

Inventor： Daisuke Kameoka ,  Toru Yoshizawa ,  Megumi Numata ,  Hitoshi Sasaki ,  So Yamaguchi ,  Hiroko Murata ,  Naoka Hironiwa

IPC: C07K16/28 ,  A61K39/395 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K9/08 ,  A61K9/19 ,  C07K14/715 ,  A61K39/00

Abstract: In one non-limiting embodiment, the present disclosure relates to lyophilized formulations containing an IL-31 antagonist (for example, an anti-IL-31RA antibody) as an active ingredient, the lyophilized formulations further containing arginine and/or a salt thereof and sucrose and/or trehalose. In another non-limiting embodiment, the present disclosure relates to solution formulations containing an IL-31 antagonist as an active ingredient, the solution formulations further containing arginine and/or a salt thereof. In other non-limiting embodiments, the present disclosure relates to methods for stabilizing an antibody (for example, an anti-IL-31RA antibody) in an antibody-containing formulation, methods for suppressing antibody aggregation (aggregate formation) in an antibody-containing formulation, and methods for reducing components with charge heterogeneity in an antibody-containing formulation, the methods being characterized in that the formulation is prepared to contain arginine and/or a salt thereof, and/or sucrose and/or trehalose.

公开(公告)号：US11168139B2

公开(公告)日：2021-11-09

申请号：US16463222

申请日：2017-11-28

Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA

Inventor： Tomoyuki Igawa ,  Hiroyuki Ishikawa ,  Naoka Hironiwa

IPC: C40B40/10 ,  C07K16/28 ,  C07K16/30 ,  G01N33/68

Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.